DE69624907D1 - Orale, pharmazeutische darreichungsformen, die einen protonenpumpeninhibitor und ein antacidum oder alginat enthalten - Google Patents

Orale, pharmazeutische darreichungsformen, die einen protonenpumpeninhibitor und ein antacidum oder alginat enthalten

Info

Publication number
DE69624907D1
DE69624907D1 DE69624907T DE69624907T DE69624907D1 DE 69624907 D1 DE69624907 D1 DE 69624907D1 DE 69624907 T DE69624907 T DE 69624907T DE 69624907 T DE69624907 T DE 69624907T DE 69624907 D1 DE69624907 D1 DE 69624907D1
Authority
DE
Germany
Prior art keywords
pharmaceutical
antacidum
alginate
proton pump
pump inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69624907T
Other languages
English (en)
Other versions
DE69624907T2 (de
DE69624907T3 (de
Inventor
Helene Depui
Agneta Hallgren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20400969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69624907(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69624907D1 publication Critical patent/DE69624907D1/de
Publication of DE69624907T2 publication Critical patent/DE69624907T2/de
Application granted granted Critical
Publication of DE69624907T3 publication Critical patent/DE69624907T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
DE69624907T 1996-01-08 1996-12-20 Orale, pharmazeutische darreichungsformen, die einen protonenpumpeninhibitor und ein antacidum oder alginat enthalten Expired - Lifetime DE69624907T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9600071 1996-01-08
SE9600071A SE9600071D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients I
PCT/SE1996/001737 WO1997025066A1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate

Publications (3)

Publication Number Publication Date
DE69624907D1 true DE69624907D1 (de) 2003-01-02
DE69624907T2 DE69624907T2 (de) 2003-08-21
DE69624907T3 DE69624907T3 (de) 2010-01-14

Family

ID=20400969

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624907T Expired - Lifetime DE69624907T3 (de) 1996-01-08 1996-12-20 Orale, pharmazeutische darreichungsformen, die einen protonenpumpeninhibitor und ein antacidum oder alginat enthalten

Country Status (35)

Country Link
US (1) US6183776B1 (de)
EP (1) EP0813424B2 (de)
JP (1) JPH11501950A (de)
KR (1) KR100490075B1 (de)
CN (1) CN1080125C (de)
AR (1) AR005281A1 (de)
AT (1) ATE228009T1 (de)
AU (1) AU712669B2 (de)
BR (1) BR9607350B1 (de)
CA (1) CA2213996C (de)
CZ (1) CZ293583B6 (de)
DE (1) DE69624907T3 (de)
DK (1) DK0813424T4 (de)
EE (1) EE04002B1 (de)
EG (1) EG23821A (de)
ES (1) ES2185817T5 (de)
HK (2) HK1001763A1 (de)
HU (1) HU229153B1 (de)
IL (1) IL121651A (de)
IS (1) IS2716B (de)
MX (1) MX9706785A (de)
MY (1) MY116091A (de)
NO (1) NO326656B1 (de)
NZ (1) NZ325977A (de)
PL (1) PL187075B1 (de)
PT (1) PT813424E (de)
RU (1) RU2179453C2 (de)
SA (1) SA97170553B1 (de)
SE (1) SE9600071D0 (de)
SK (1) SK283695B6 (de)
TR (1) TR199700916T1 (de)
TW (1) TW464514B (de)
UA (1) UA45392C2 (de)
WO (1) WO1997025066A1 (de)
ZA (1) ZA9610935B (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US8071128B2 (en) * 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
WO1998023272A1 (en) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders
MX9703918A (es) * 1997-05-28 1998-11-30 J Marshall M D Barry Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior.
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
JP2001513570A (ja) * 1997-08-25 2001-09-04 ザ、プロクター、エンド、ギャンブル、カンパニー 上部胃腸管不調治療用複合製剤
SI1037634T1 (sl) * 1997-12-08 2006-02-28 Altana Pharma Ag Peroralna dajalna oblika, ki obsega inhibitor protonske crpalke (npr. pantoprazol)
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
FR2774906B1 (fr) * 1998-02-13 2000-05-12 Rhodia Chimie Sa Systeme d'encapsulation a coeur organique et a ecorce minerale a base d'hydroxycarbonate d'aluminium et son procede de preparation
KR101032289B1 (ko) 1998-05-18 2011-05-06 다케다 야쿠힌 고교 가부시키가이샤 미세과립
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
ES2237121T3 (es) 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
EP1244430A4 (de) * 1999-03-29 2004-01-14 Wyeth Corp Beschichtungssystem
JP2003504338A (ja) * 1999-07-12 2003-02-04 スミスクライン・ビーチャム・コーポレイション 胸やけの処置法
DK1222922T3 (da) 1999-10-20 2007-12-03 Eisai R&D Man Co Ltd Fremgangsmåde til stabilisering af benzimidazolforbindelser
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CA2453290A1 (en) * 2001-07-16 2003-01-30 Astrazeneca Ab Pharmaceutical formulation comprising a proton pump inhibitor and antacids
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
MXPA04002979A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosificacion de liberacion modificada.
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7008777B2 (en) 2001-10-15 2006-03-07 Barry J. Marshall System for the detection of urease and method for using same
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
KR100479637B1 (ko) * 2002-02-01 2005-03-31 한국화학연구원 란소프라졸을 함유하는 경구제제 및 그의 제조방법
CO5400144A1 (es) 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
IL164222A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040081700A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Dose titratable liquid dosage forms of acid labile drugs
US6663892B1 (en) * 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
WO2004035052A1 (ja) * 2002-10-16 2004-04-29 Takeda Pharmaceutical Company Limited 安定な固形製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7258981B2 (en) * 2003-01-24 2007-08-21 Clontech Laboratories, Inc. Sensitive proteasome sensor constructs and methods for their design and use
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
EP1759692A3 (de) * 2003-03-10 2007-09-12 Novartis AG Geschmacksüberdeckte feste arzneiformen für Tiere
CN100342860C (zh) * 2003-03-18 2007-10-17 兴和株式会社 抗酸剂组合物
WO2004112756A1 (en) * 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1648416A4 (de) * 2003-07-18 2012-03-28 Santarus Inc Pharmazeutische formulierungen zur hemmung der säuresekretion und herstellungs- und anwendungsverfahren
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
US7252665B2 (en) * 2003-10-31 2007-08-07 Medtronic, Inc Ablation of stomach lining to reduce stomach acid secretion
US7282050B2 (en) * 2003-10-31 2007-10-16 Medtronic, Inc. Ablation of exterior of stomach to treat obesity
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US7041124B2 (en) * 2003-12-23 2006-05-09 Kimberly-Clark Worldwide, Inc. System and method for providing therapy to a portion of a body
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070224269A1 (en) * 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) * 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
SE530605C2 (sv) * 2005-09-29 2008-07-15 Barbara Nelson Läkemedel innehållande ett syrahämmande medel, avseende att användas för att motverka och bota luftvägssjukdomar
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
RU2496480C2 (ru) * 2005-12-28 2013-10-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат с контролируемым высвобождением
CN101453993A (zh) * 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US20090068263A1 (en) * 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー. 複式ユニット製薬的製剤
AR056062A1 (es) 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术(石家庄)有限公司 一种奥美拉唑组合物及其制备方法
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (de) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Vorrichtung mit mehreren Kammern und Dispenser
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CN101259140B (zh) * 2007-03-08 2012-08-22 重庆北碚现代应用药物研究所 一种治疗胃炎、胃溃疡及十二指肠溃疡的复方药物及其制备方法
DK2152250T3 (da) * 2007-05-07 2019-12-09 Evonik Degussa Gmbh Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse
EP2044929A1 (de) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Schnell lösliche Tabletten für orale Anwendung
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
EP2127643A1 (de) * 2008-05-30 2009-12-02 Bayer Schering Pharma Aktiengesellschaft Orale Pelletformulierungen mit zeitversetzter Wirkstofffreigabe
EP2344139A1 (de) 2008-09-09 2011-07-20 AstraZeneca AB Verfahren zur abgabe einer pharmazeutischen zusammensetzung an einen patienten, der diese benötigt
WO2010038241A2 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Nsaid関連潰瘍を発症するリスクがある患者の処置方法
WO2010151697A1 (en) * 2009-06-25 2010-12-29 Pozen Inc. Method for treating a patient in need of aspirin therapy
CN108159019A (zh) 2009-12-02 2018-06-15 阿黛尔药物有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
WO2011080501A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
TW201127375A (en) * 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
EA024050B1 (ru) 2010-04-23 2016-08-31 С-БИОТЕК ХОЛДИНГ АпС Твердая фармацевтическая композиция для нейтрализации желудочной кислоты
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US20150238514A1 (en) * 2014-02-21 2015-08-27 William Armstrong Protective Supplement Configuration
EP3288556A4 (de) * 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
SG11201809555QA (en) * 2016-04-29 2018-11-29 Alan Thompson Veterinary composition
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TR201723199A2 (tr) * 2017-12-30 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Yeni farmasötik bileşimler.
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
JP2021533177A (ja) * 2018-08-23 2021-12-02 チョン クン ダン ファーマシューティカル コーポレイション エソメプラゾール及び炭酸水素ナトリウムを含む、優れた溶解特性を備えた薬学的製剤
WO2021075926A1 (ko) * 2019-10-17 2021-04-22 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 약학적 조성물
US20230058432A1 (en) * 2020-01-23 2023-02-23 Hanmi Pharm. Co., Ltd. Pharmaceutical composite formulation comprising proton pump inhibitor and antacid
EP4070789A4 (de) * 2020-01-23 2024-01-24 Hanmi Pharm Ind Co Ltd Pharmazeutische verbundformulierung mit protonenpumpenhemmer und antazidum
KR102608889B1 (ko) * 2020-07-14 2023-12-04 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법
KR20220065997A (ko) * 2020-11-13 2022-05-23 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
KR20230097346A (ko) * 2021-12-24 2023-07-03 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 경구용 복합정제의 제조방법 및 이에 의해 제조된 경구용 복합정제
KR102553713B1 (ko) * 2022-11-18 2023-07-10 고덕상 미네랄 촉매제를 이용한 양식어류사료 제조방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
WO1985003436A1 (en) 1984-02-10 1985-08-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
US4568560A (en) 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
WO1987004077A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
US5112813A (en) 1986-03-07 1992-05-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Process for the preparation of a viscosity-stable antacid composition
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DK179687D0 (da) 1987-04-08 1987-04-08 Farma Food As Praeparat
KR960011236B1 (ko) 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형
EP0294933B1 (de) 1987-05-08 1992-03-11 Smith Kline & French Laboratories Limited Pharmazeutische Zusammensetzungen
GB8809421D0 (en) * 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
NL8902338A (nl) 1988-09-20 1990-04-17 Glaxo Group Ltd Farmaceutische preparaten.
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
DE4023028A1 (de) * 1990-07-20 1992-01-23 Hoechst Ag Ferroelektrische fluessigkristalline si-enthaltende copolymere, ein verfahren zu ihrer herstellung, mischungen dieser copolymere mit niedermolekularen fluessigkristallen und die verwendung in elektrooptischen bauteilen
US5244670A (en) * 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3142919B2 (ja) 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5229137A (en) 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
US5447918A (en) 1992-07-27 1995-09-05 Mccullough; Ricky W. Gastrointestinal anti-irritant composition comprising sucralfate and methods of use
JPH07509702A (ja) 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
CA2110313C (en) 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
WO1995001780A1 (en) 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate combinations
CA2166731A1 (en) 1993-07-06 1995-01-19 Robert T. Sims H2 antagonist-alginate-antacid combinations
AU7833194A (en) 1993-09-20 1995-04-10 Procter & Gamble Company, The Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
AU683092B2 (en) 1993-10-12 1997-10-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Tablet containing enteric granules
GB2285989A (en) 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
AUPM596894A0 (en) 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
US5817338A (en) 1994-07-08 1998-10-06 Astra Aktiebolag Multiple unit tableted dosage form of omeprazole
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
AUPM695294A0 (en) 1994-07-20 1994-08-11 Borody, Thomas Julius Improved combination therapy dose unit
WO1996029055A1 (en) 1995-03-17 1996-09-26 The Boots Company Plc Pectin liquid pharmaceutical compositions
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1998023272A1 (en) 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
CA2213996A1 (en) 1997-07-17
CN1080125C (zh) 2002-03-06
KR19980702829A (ko) 1998-08-05
EP0813424B1 (de) 2002-11-20
PL187075B1 (pl) 2004-05-31
HU229153B1 (en) 2013-09-30
EP0813424A1 (de) 1997-12-29
EP0813424B2 (de) 2009-08-05
PL322175A1 (en) 1998-01-19
ZA9610935B (en) 1997-07-08
AU1324197A (en) 1997-08-01
ES2185817T3 (es) 2003-05-01
IS2716B (is) 2011-02-15
IS4548A (is) 1997-08-20
JPH11501950A (ja) 1999-02-16
HK1017992A1 (en) 1999-12-10
NO974071L (no) 1997-10-17
HUP9904024A3 (en) 2002-03-28
SA97170553B1 (ar) 2006-06-04
EG23821A (en) 2007-09-19
IL121651A0 (en) 1998-02-08
KR100490075B1 (ko) 2005-09-08
CZ274797A3 (cs) 1998-03-18
IL121651A (en) 2003-05-29
MX9706785A (es) 1997-11-29
EE04002B1 (et) 2003-04-15
SK283695B6 (sk) 2003-12-02
AR005281A1 (es) 1999-04-28
DE69624907T2 (de) 2003-08-21
NO974071D0 (no) 1997-09-04
DK0813424T3 (da) 2003-03-10
CZ293583B6 (cs) 2004-06-16
BR9607350A (pt) 1997-12-30
SK116997A3 (en) 1998-05-06
AU712669B2 (en) 1999-11-11
CN1183047A (zh) 1998-05-27
RU2179453C2 (ru) 2002-02-20
SE9600071D0 (sv) 1996-01-08
TW464514B (en) 2001-11-21
BR9607350B1 (pt) 2010-08-10
EE9700192A (et) 1998-02-16
TR199700916T1 (xx) 1997-12-21
WO1997025066A1 (en) 1997-07-17
DK0813424T4 (da) 2009-11-09
MY116091A (en) 2003-11-28
HK1001763A1 (en) 1998-07-10
DE69624907T3 (de) 2010-01-14
ES2185817T5 (es) 2009-11-24
ATE228009T1 (de) 2002-12-15
UA45392C2 (uk) 2002-04-15
US6183776B1 (en) 2001-02-06
PT813424E (pt) 2003-03-31
CA2213996C (en) 2006-08-29
NZ325977A (en) 1999-02-25
NO326656B1 (no) 2009-01-26
HUP9904024A2 (hu) 2000-05-28

Similar Documents

Publication Publication Date Title
DE69624907D1 (de) Orale, pharmazeutische darreichungsformen, die einen protonenpumpeninhibitor und ein antacidum oder alginat enthalten
ATE228010T1 (de) Orale pharmazeutische dosierungsformen die einen protonenpumpeninhibitor und ein prokinetisches mittel enthalten
DK0814839T3 (da) Orale, farmaceutiske doseringsformer omfattende en protonpumpeinhibitor og et NSAID
DE69600065T2 (de) Dermatologische und/oder pharmazeutische Zubereitung, ihre Herstellung und Anwendung
ID21115A (id) Isokuinolin-3-karboksamida tersubstitusi, pembuatannya serta penggunaannya sebagai obat
DE69525148T2 (de) Pharmazeutische formulierung
DE638294T1 (de) Mundpflege Einrichtung.
IS5639A (is) Þrýstings/afls tölvustýrt lyfjaskömmtunarkerfi ogþví um líkt
DE69509134D1 (de) Doppelbankspeicher und systeme, die diesen benutzen
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
NO975513D0 (no) 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel
ATE252096T1 (de) Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
DZ1926A1 (fr) Formulations pharmaceutiques.
TR199501553A2 (tr) Sefem bilesimleri ve bunlarin farmasötik olarak kullanilmasi.
DE69621969T2 (de) Ein total hygienisches wasserpneumatisches System, verwendbar in zahnärztlichen Geräten
KR960030598U (ko) 이,미용원용가습장치
DE68906245T2 (de) Therapeutisches Mittel gegen Aids.
DE19681529D2 (de) Pharmazeutische Darreichungsform
IS4740A (is) Nýjar kínoxalindíón afleiður, framleiðsla þeirra og notkun í læknislyf
PT1235809E (pt) 1,2,3,4,5,6-hexa-hidro-2,6-metano-3-benzazocinas substituidas e sua utilizacao como medicamentos
NL193607B (nl) Farmaceutisch preparaat dat N-acetylcysteïne bevat.
DE29522015U1 (de) Pharmazeutische Zusammensetzungen, die Lycopin umfassen
ES1029315Y (es) Estructura de camilla para estetica y medicina, mejorada.
DE29503674U1 (de) Zerlegbarer Patienten-Lothublifter in Leichtausführung
KR950005570U (ko) 한약재 농축기

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings